Advanced search
Publication Cover
Leukemia & Lymphoma Volume 62, 2021 - Issue 11
Submit an article Journal homepage
206
Views
0
CrossRef citations to date
0
Altmetric
Letters to the Editor

Mutations known from B-cell lymphoid malignancies are not found in CD34+ stem cells from patients with lymphoma

Simon Husbya Department of Hematology, Rigshospitalet, Copenhagen, Denmark;b Biotech Research and Innovation Centre, University of Copenhagen, Copenhagen, Denmark;c Faculty of Health Sciences, Novo Nordisk Foundation Center for Stem Cell Biology, DanStem, University of Copenhagen, Copenhagen, DenmarkCorrespondence[email protected]
View further author information
,
Francesco Faverob Biotech Research and Innovation Centre, University of Copenhagen, Copenhagen, Denmark;d Finsen Laboratory, Rigshospitalet, Copenhagen, DenmarkView further author information
,
Francisco G. Rodriguez-Gonzalezb Biotech Research and Innovation Centre, University of Copenhagen, Copenhagen, Denmark;d Finsen Laboratory, Rigshospitalet, Copenhagen, DenmarkView further author information
,
Lesley A. Suttone Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, SwedenView further author information
,
Eva K. Haastrupf Department of Clinical Immunology, Rigshospitalet, Copenhagen, DenmarkView further author information
,
Andreas Due Ørskova Department of Hematology, Rigshospitalet, Copenhagen, Denmark;b Biotech Research and Innovation Centre, University of Copenhagen, Copenhagen, DenmarkView further author information
,
Jakob W. Hansena Department of Hematology, Rigshospitalet, Copenhagen, Denmark;b Biotech Research and Innovation Centre, University of Copenhagen, Copenhagen, Denmark;c Faculty of Health Sciences, Novo Nordisk Foundation Center for Stem Cell Biology, DanStem, University of Copenhagen, Copenhagen, DenmarkView further author information
,
Bente Arboeb Biotech Research and Innovation Centre, University of Copenhagen, Copenhagen, DenmarkView further author information
,
Derya Aslana Department of Hematology, Rigshospitalet, Copenhagen, Denmark;b Biotech Research and Innovation Centre, University of Copenhagen, Copenhagen, DenmarkView further author information
,
Erik Clasen-Lindeg Department of Pathology, Rigshospitalet, Copenhagen, DenmarkView further author information
,
Lise Mette Rahbek Gjerdrumh Department of Pathology, Zealand University Hospital, Roskilde, DenmarkView further author information
,
Jette Sønderskov Gørleva Department of Hematology, Rigshospitalet, Copenhagen, DenmarkView further author information
,
Peter Browna Department of Hematology, Rigshospitalet, Copenhagen, DenmarkView further author information
,
Anne Fischer-Nielsenf Department of Clinical Immunology, Rigshospitalet, Copenhagen, DenmarkView further author information
,
Richard Rosenquiste Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, SwedenView further author information
,
Joachim Weischenfeldtb Biotech Research and Innovation Centre, University of Copenhagen, Copenhagen, Denmark;d Finsen Laboratory, Rigshospitalet, Copenhagen, DenmarkView further author information
&
Kirsten Grønbæka Department of Hematology, Rigshospitalet, Copenhagen, Denmark;b Biotech Research and Innovation Centre, University of Copenhagen, Copenhagen, Denmark;c Faculty of Health Sciences, Novo Nordisk Foundation Center for Stem Cell Biology, DanStem, University of Copenhagen, Copenhagen, DenmarkView further author information
 show all
Pages 2808-2811 | Received 01 Dec 2020, Accepted 11 May 2021, Published online: 21 Jun 2021

References

  • Gisselbrecht C, Glass B, Mounier N, et al. Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era. J Clin Oncol. 2010;28(27):4184–4190.
  • Schmitz N, Pfistner B, Sextro M, et al. Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin’s disease: a randomised trial. Lancet (London, England). 2002;359(9323):2065–2071.
  • Arboe B, Halgren Olsen M, Duun-Henriksen AK, et al. Prolonged hospitalization, primary refractory disease, performance status and age are prognostic factors for survival in patients with diffuse large B-cell lymphoma and transformed indolent lymphoma undergoing autologous stem cell transplantation. Leuk Lymphoma. 2018;59(5):1153–1162.
  • Bröckelmann PJ, Müller H, Casasnovas O, et al. Risk factors and a prognostic score for survival after autologous stem-cell transplantation for relapsed or refractory Hodgkin lymphoma. Ann Oncol. 2017;28(6):1352–1358.
  • Gibson CJ, Lindsley RC, Tchekmedyian V, et al. Clonal hematopoiesis associated with adverse outcomes after autologous stem-cell transplantation for lymphoma. J Clin Oncol. 2017;35(14):1598–1605.
  • Husby S, Favero F, Nielsen C, et al. Clinical impact of clonal hematopoiesis in patients with lymphoma undergoing ASCT: a national population-based cohort study. Leukemia. 2020;34(12):3256–3268.
  • Arends CM, Galan-Sousa J, Hoyer K, et al. Hematopoietic lineage distribution and evolutionary dynamics of clonal hematopoiesis. Leukemia. 2018;32(9):1908–1919.
  • Buscarlet M, Provost S, Zada YF, et al. Lineage restriction analyses in CHIP indicate myeloid bias for TET2 and multipotent stem cell origin for DNMT3A. Blood. 2018;132(3):277–280.
  • Jaiswal S, Fontanillas P, Flannick J, et al. Age-related clonal hematopoiesis associated with adverse outcomes. N Engl J Med. 2014;371(26):2488–2498.
  • Genovese G, Kähler AK, Handsaker RE, et al. Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence. N Engl J Med. 2014;371(26):2477–2487.
  • Tate JG, Bamford S, Jubb HC, et al. COSMIC: the catalogue of somatic mutations in cancer. Nucleic Acids Res. 2019;47(D1):D941–D947.
  • Scourzic L, Couronné L, Pedersen MT, et al. DNMT3A(R882H) mutant and Tet2 inactivation cooperate in the deregulation of DNA methylation control to induce lymphoid malignancies in mice. Leukemia. 2016;30(6):1388–1398.
  • Husby S, Grønbaek K. Mature lymphoid malignancies: origin, stem cells, and chronicity. Blood Adv. 2017;1(25):2444–2455.
  • Horton SJ, Giotopoulos G, Yun H, et al. Early loss of CREBBP confers malignant stem cell properties on lymphoid progenitors. Nat Cell Biol. 2017;19(9):1093–1104.
  • Wong TN, Miller CA, Jotte MRM, et al. Cellular stressors contribute to the expansion of hematopoietic clones of varying leukemic potential. Nat Commun. 2018;9(1):455.
  • Lindsley RC, Saber W, Mar BG, et al. Prognostic mutations in myelodysplastic syndrome after stem-cell transplantation. N Engl J Med. 2017;376(6):536–547.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.